COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022

Euro Surveill. 2022 May;27(18):2200322. doi: 10.2807/1560-7917.ES.2022.27.18.2200322.

Abstract

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

Keywords: SARS-CoV-2 vaccine effectiveness; epidemiological surveillance; variant of concern.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2*
  • Sweden / epidemiology
  • Vaccine Efficacy

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants